HomeCompareBJCHF vs PFE

BJCHF vs PFE: Dividend Comparison 2026

BJCHF yields 606.06% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BJCHF wins by $414.9K in total portfolio value
10 years
BJCHF
BJCHF
● Live price
606.06%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$464.5K
Annual income
$1,393.28
Full BJCHF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — BJCHF vs PFE

📍 BJCHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBJCHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BJCHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BJCHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BJCHF
Annual income on $10K today (after 15% tax)
$51,515.15/yr
After 10yr DRIP, annual income (after tax)
$1,184.29/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,135.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BJCHF + PFE for your $10,000?

BJCHF: 50%PFE: 50%
100% PFE50/50100% BJCHF
Portfolio after 10yr
$257.0K
Annual income
$13,826.00/yr
Blended yield
5.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BJCHF
No analyst data
Altman Z
0.2
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BJCHF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBJCHFPFE
Forward yield606.06%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$464.5K$49.6K
Annual income after 10y$1,393.28$26,258.71
Total dividends collected$285.8K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BJCHF vs PFE ($10,000, DRIP)

YearBJCHF PortfolioBJCHF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$41,003$30,303.03$9,153$693.39+$31.9KBJCHF
2$101,935$58,061.50$8,593$849.25+$93.3KBJCHF
3$176,520$67,449.81$8,336$1,066.78+$168.2KBJCHF
4$243,457$54,580.64$8,437$1,384.80+$235.0KBJCHF
5$295,676$35,176.55$9,013$1,875.40+$286.7KBJCHF
6$336,336$19,963.31$10,306$2,680.72+$326.0KBJCHF
7$370,491$10,611.51$12,820$4,101.38+$357.7KBJCHF
8$401,888$5,462.20$17,673$6,826.70+$384.2KBJCHF
9$432,789$2,768.73$27,543$12,591.86+$405.2KBJCHF
10$464,477$1,393.28$49,560$26,258.71+$414.9KBJCHF

BJCHF vs PFE: Complete Analysis 2026

BJCHFStock

Beijing Capital International Airport Company Limited engages in the aeronautical and non-aeronautical businesses at the Beijing Capital Airport in the People's Republic of China. The company's aeronautical business is involved in the provision of aircraft landings and take-offs; passenger service facilities; ground support services; and fire-fighting services for domestic and foreign air transportation enterprises. Its non-aeronautical business includes the franchise-based operation of ground handling agent services for domestic and foreign airliners; in-flight catering services; duty free and other retail shops in the terminals, as well as restaurants and other catering businesses in terminals; leasing advertising spaces inside and outside the terminals; and other businesses. The company's non-aeronautical business also comprises the leasing of properties in the terminals; provision of car parking services; and provision of ground handling facilities for ground handling agent companies. As of December 31, 2021, the company had 85 airliners operating fixed commercial flights at the Beijing Capital Airport, including 26 domestic airliners and 59 airliners from foreign countries; and operated 208 flight points linking with the Beijing Capital Airport, including 133 domestic flight points and 75 international flight points. The company was incorporated in 1999 and is based in Beijing, the People's Republic of China. Beijing Capital International Airport Company Limited is a subsidiary of Capital Airports Holding Limited.

Full BJCHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BJCHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BJCHF vs SCHDBJCHF vs JEPIBJCHF vs OBJCHF vs KOBJCHF vs MAINBJCHF vs JNJBJCHF vs MRKBJCHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.